Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 57Recurrence 7Neoplasms, Plasma Cell 5Neoplasms 4Smoldering Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Immunoglobulin Light-chain Amyloidosis 1Glioblastoma 1Disease 1Chromosome 17 deletion 1

Interventions

pembrolizumab 1neratinib 1daratumumab 1Molecular Docking Simulation 1Fluorodeoxyglucose F18 1Equipment and Supplies 1Cyclophosphamide 1Blood Specimen Collection 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Disease × daratumumab × Clear all
NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

European Myeloma Network B.V.

Phase 2 Active not recruiting
401 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡